SCHEMBL403118

SCHEMBL403118

CC(=O)NC1COC(COS(=O)(=O)O)C[C@H]1O

nearest known ligand 0.40

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.30
CYP2C19 P33261 1/20 0.30
OGA O60502 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11937054 1.00 CYP2C9 (0.30) CYP2C9CYP2C19OGA
SCHEMBL10045291 0.84
SCHEMBL10357880 0.82
SCHEMBL10045290 0.82
SCHEMBL11934549 0.82
SCHEMBL12154036 0.82
SCHEMBL403204 0.82
SCHEMBL24943576 0.78 OGA (0.41) CYP2C9CYP2C19OGA
SCHEMBL10023957 0.78 OGA (0.41) CYP2C9CYP2C19OGA
SCHEMBL12902089 0.78 OGA (0.41) CYP2C9CYP2C19OGA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160310521-A1 POLYSACCHARIDES COMPRISING TWO ANTITHROMBIN III-BINDING SITES, PREPARATION THEREOF AND USE THEREOF AS ANTITHROMBOTIC MEDICAMENTS SANOFI (FR) 2016-10-27 US disclosed
US-8501711-B2 Acylated 1,6-anhydro decasaccharide and its use as an antithrombotic agent SANOFI (FR) 2013-08-06 US disclosed
US-20120108541-A1 ACYLATED 1,6-ANHYDRO DECASACCHARIDE AND ITS USE AS AN ANTITHROMBOTIC AGENT SANOFI (FR) 2012-05-03 US disclosed
US-20120065153-A1 AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF SANOFI-AVENTIS (FR) 2012-03-15 US disclosed
US-20070270354-A1 Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof SANOFI-AVENTIS (FR) 2007-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160310521-A1 POLYSACCHARIDES COMPRISING TWO ANTITHROMBIN III-BINDING SITES, PREPARATION THEREOF AND USE THEREOF AS ANTITHROMBOTIC MEDICAMENTS SERPINC1, F13B, F12 CYP2C9 1313/4885CYP2C19 2463/4885OGA 1139/4885
US-20120065153-A1 AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF HPSE, HAAO, HEXD CYP2C9 307/4885CYP2C19 721/4885OGA 76/4885
US-20070270354-A1 Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof HPSE, HAAO, HEXD CYP2C9 298/4885CYP2C19 695/4885OGA 68/4885
US-20120108541-A1 ACYLATED 1,6-ANHYDRO DECASACCHARIDE AND ITS USE AS AN ANTITHROMBOTIC AGENT FUT6, FUT5, CSGALNACT1 CYP2C9 614/4885CYP2C19 816/4885OGA 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.